Abstract:Editor-in-Chief, reviews two of the most remarkable papers published in The Chinese Journal of Cardiology (CJC). Transcatheter aortic valve replacement (TAVR) has become an established and increasingly used approach for the management of severe symptomatic aortic stenosis (AS) or regurgitation throughout the surgical risk spectrum, showing similar, or even superior outcomes compared with standard surgical aortic valve replacement. Despite an iteration in TAVR device technologies and improved patient selection and management through the multidisciplinary heart teams, challenges, and controversies exist regarding the balancing of ischaemic and bleeding risks in these patients and the optimal antithrombotic regimens to adopt after TAVR are still unclear. This was recently reported in the CJC with a contribution entitled ‘One-year follow-up results of atrial fibrillation (AF) patients who undergoing transcatheter aortic valve implantation’ by Prof. Yaling Han and colleagues from General Hospital of Northern Theater Command. This is a single-centre retrospective study. A total of 115 patients with severe AS who were admitted to the hospital from May 2016 to November 2020 and successfully received TAVR were included. According to the absence or presence of AF pre-TAVR, they were divided into the AF group (n= 21) and the non-AF group (n= 94). The patients were followed up for postoperative antithrombotic treatment and the occurrence of the net adverse clinical and cerebrovascular events (NACCEs) at 12 months post-TAVR, including cardiac death, readmission to hospital for heart failure, non-fatal myocardial infarction, ischaemic stroke, and major bleeding [Bleeding Academic Research Consortium (BARC) levels 3–5]. Among the 115 selected patients, age was (73.8+ 6.9) years, there were 63 males. In terms of postoperative antithrombotic therapy, 48.9% (46/94) of the patients in the non-AF group received monotherapy and 47.9% (45/94) received dual antiplatelet therapy (DAPT). In the AF group, 47.6% (10/21) received anticoagulants and 33.3% (7/21) received DAPT. The proportion of patients in the AF group taking non-vitamin K antagonist oral anticoagulants (NOACs) was higher than that in the non-AF group [38.1% (8/21) vs. 2.1% (2/94), P, 0.001]. During the 12 months follow-up, the incidence of NACCE after TAVR was 14.3% (3/21) in the AF group, which was numerically higher than that in the non-AF group [6.4% (6/94)], while the difference was not statistically significant (P= 0.441, Table 1). The incidence of major bleeding was significantly higher in the AF group than in the non-AF group [9.5% (2/21) vs. 0.0%, P= 0.032, Table 1]. Univariate logistic regression analysis showed that hypertension was associated with the risk of NACCE (OR= 8.308, P= 0.050), while AF was not associated with the risk of NACCE (P= 0.235). Therefore, the incidence of severe bleeding after TAVR is higher in

Clinical Outcomes of Early Rhythm or Rate Control for New Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement

Impact of new-onset versus pre-existing atrial fibrillation on outcomes after transcatheter aortic valve replacement/implantation

Rhythm Outcomes After Aortic Valve Surgery: Treatment And Evolution Of New-Onset Atrial Fibrillation

Cardiovascular Outcomes With an Early Rhythm Control Strategy in Atrial Fibrillation: A Systematic Review

Atrial fibrillation before and after transcatheter aortic valve implantation: short- and long-term clinical implications

Midterm Outcome of Transcatheter Versus Surgical Aortic Valve Replacement in Low to Intermediate Risk Patients: A Meta-Analysis of Randomized Controlled Trials.

A pilot study to assess benefit of atrial rhythm control after cardiac resynchronization therapy and atrioventricular node ablation

Short- and intermediate-term outcomes of transcatheter aortic valve replacement in low-risk patients: A meta-analysis and systematic review

Impact of Persistent Versus Paroxysmal Preoperative Atrial Fibrillation on In-Hospital, One-Year, and Late Clinical Outcomes Following Transcatheter Aortic Valve Implantation

Renal Outcomes of Rhythm Control in Patients Recently Diagnosed With Atrial Fibrillation

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement

Comparison of the outcome between patients with new-onset atrial fibrillation and patients retained sinus rhythm after cardiac resynchronization therapy

Outcomes of catheter ablation versus antiarrhythmic therapy in patients with atrial fibrillation: a systematic review and meta-analysis

Real-World Outcomes of a Rhythm Control Strategy for Atrial Fibrillation Patients with Reduced Left Ventricular Ejection Fraction (<50%)

Impact of cardiac rehabilitation on pre- and post-operative transcatheter aortic valve replacement prognoses

Pharmacological cardioversion of atrial fibrillation: current management and treatment options

Catheter ablation for atrial fibrillation and impact on clinical outcomes

Factors influencing early recurrence of atrial fibrillation among elderly patients following radiofrequency catheter ablation and the impact of different antiarrhythmic regimens

Effect of Early Pharmacologic Cardioversion Vs. Non-early Cardioversion in the Patients with Recent-Onset Atrial Fibrillation Within 4-Week Follow-Up Period: A Systematic Review and Network Meta-Analysis

Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review

Rhythm and rate control strategies in patients with long-standing persistent atrial fibrillation treated with cardiac resynchronization: the results of the randomized Pilot-CRAfT study